A phase II study of oral fluorouracil for gastrointestinal cancer.

Cartei, F; Cartei, G; Giraldi, T; Interlandi, G; Meneghini, G; Imperato, A; Vigevani, E; Tabaro, G

Cartei, F; Cartei, G; Giraldi, T; Interlandi, G; Meneghini, G; Imperato, A; Vigevani, E; Tabaro, G.

Affiliation

Cartei F; Radiotherapy Division, Hospital (Azienda Nazionale) S. Chiara, Pisa, Italy.

Anticancer Drugs ; 7(1): 48-53, 1996 Jan.

Article in En | MEDLINE | ID: mdl-8742098

Subject(s)

Antimetabolites, Antineoplastic/administration & dosage; Fluorouracil/administration & dosage; Gastrointestinal Neoplasms/drug therapy; Adult; Aged; Antimetabolites, Antineoplastic/adverse effects; Combined Modality Therapy; Diarrhea/chemically induced; Drug Administration Schedule; Female; Fluorouracil/adverse effects; Humans; In Vitro Techniques; Male; Middle Aged; Prospective Studies

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Fluorouracil / Gastrointestinal Neoplasms / Antimetabolites, Antineoplastic Type of study: Observational_studies / Risk_factors_studies Aspects: Patient_preference Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 1996 Document type: Article Affiliation country: Italy

Search on Google

Add to My VHL

XML

PubMed Links